Metformin’s hidden brain pathway revealed after 60 years as 2025 study shifts thinking

metformin, prescribed for more than six decades to manage type 2 diabetes, has been shown in a 2025 study to act directly in the brain — a finding that reframes how the drug lowers blood sugar and opens new avenues for targeted therapies.

What Happens Now That metformin Appears to Work in the Brain?

The research team at Baylor College of Medicine identified a brain-based mechanism in the ventromedial hypothalamus (VMH) centered on a small protein called Rap1. Makoto Fukuda, associate professor of pediatrics – nutrition at Baylor College of Medicine, led the work published in Science Advances that links metformin’s glucose-lowering effect to suppression of Rap1 activity in the VMH.

Key experimental findings in mice, drawn from the study, are: metformin travels to the VMH and effectively turns off Rap1; mice genetically engineered to lack Rap1 in that region did not experience blood sugar improvement with metformin even when other diabetes treatments remained effective; and delivering tiny, brain-targeted doses of metformin produced blood sugar reductions at doses far lower than standard oral dosing. The researchers also identified the specific neurons involved: SF1 neurons in the VMH are activated when metformin is introduced into the brain and require Rap1 to respond.

What If this Brain Pathway Becomes a Direct Drug Target?

Three realistic futures emerge from the study’s findings. Each is rooted in the paper’s core observations about Rap1, SF1 neurons, and differential sensitivity of brain versus liver or gut to metformin.

• Best case: The Rap1–SF1 pathway is validated in humans, allowing development of brain-directed agents that amplify metformin’s effect or replicate it at lower systemic doses. New therapies could be more potent and more focused on neural circuits that regulate whole-body glucose.
• Most likely: Human studies confirm a contributory brain pathway. Clinicians gain a clearer mechanistic picture that informs combination strategies—leveraging liver, gut, and brain actions—to optimize dosing and minimize side effects, while research explores whether the same pathway underpins other purported brain benefits of the drug.
• Most challenging: Human physiology differs enough that Rap1’s role in people is limited or variable. The neural effect seen in mice is real but insufficiently targetable or safe in humans, leaving metformin’s main clinical utility anchored to liver and gut actions and slowing translation into brain-directed treatments.

These scenarios are bounded by the study’s explicit limitations: the current evidence comes from animal models, and the authors note that confirmation in human studies is required before clinical translation.

Who Wins, Who Loses — and What Readers Should Watch?

Winners in the best and most likely scenarios include researchers focused on neural regulation of metabolism, patients who could benefit from stronger or more tailored treatments, and developers of therapies that act on brain circuits at lower systemic exposure. Losers or at-risk stakeholders could include treatment approaches that rely solely on peripheral mechanisms if the brain proves central to optimal control, and any development programs that cannot demonstrate human relevance of the Rap1 pathway.

Near-term signals to monitor (rooted in the study’s findings) are the outcomes of human studies testing whether low-dose brain exposure produces metabolic effects, confirmation of Rap1’s role in human VMH cells, and exploration of whether Rap1 signaling explains other brain-related benefits linked to the drug.

The study from Baylor College of Medicine, led by Makoto Fukuda and published in Science Advances, changes the frame: metformin is not only acting on liver and gut but very likely also through a discrete brain pathway. That reframing invites focused human research and, over time, the potential to build treatments that directly target the Rap1–SF1 circuit implicated in the VMH — a development clinicians, researchers, and people living with type 2 diabetes should track closely as the implications for practice and drug development unfold around metformin